News | July 28, 2022
Dr Lal Path Labs Q1 FY23 consolidated PAT drops to Rs. 57.7 Cr
Dr. Lal Path Labs has reported total income of Rs. 511 crores during the period ended June 30, 2022
Dr. Lal Path Labs has reported total income of Rs. 511 crores during the period ended June 30, 2022
The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park
India exported about Rs 33,321 crore and imported Rs 35,249 crore worth APIs and Bulk drugs in 2021-22.
Tealium for Pharma utilizes deep integration technology and partnerships to deliver an enhanced customer journey in one of healthcare's most vital sectors
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.
Aarti Drugs Limited has reported total income of Rs. 622.22 crores during the quarter ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
